External validation and comparison of simple ultrasound activity score and international bowel ultrasound segmental activity score for Crohn’s disease

Abstract

Background

Intestinal ultrasound (IUS) is a non-invasive tool for monitoring Crohn’s disease (CD) activity. Recently, sonographic activity scores, including the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) and Simple Ultrasound Activity Score for CD (SUS-CD), were developed. This study aimed to assess their clinical application value.

Methods

This retrospective study enrolled patients with CD from March 2021 to June 2022. The diagnostic performance of the ultrasound scores was evaluated using the simplified endoscopic score for CD (SES-CD). Correlations of ultrasound scores with SES-CD, CD activity index (CDAI), and inflammatory biomarkers were assessed. Inter-rater reliability was compared.

Results

In total, 140 patients were included. The IBUS-SAS for evaluating disease activity had an area under the curve (AUC) of 0.895, sensitivity of 85.4%, and specificity of 82.4% for the cut-off value of 48.7. The SUS-CD revealed an AUC of 0.835, sensitivity of 92.7%, and specificity of 64.7% for the cut-off value of 2.5. The IBUS-SAS and SUS-CD were positively correlated with SES-CD (r = 0.511 and 0.534, respectively). The scores correlated significantly with the CDAI and inflammatory biomarkers (all p < 0.01). The IBUS-SAS was more strongly correlated with CDAI (r = 0.666 vs 0.486) and C-reactive protein (r = 0.645 vs 0.434) than the SUS-CD. The intraclass correlation coefficient (ICC) of the IBUS-SAS and SUS-CD between the two sonologists was excellent (ICC = 0.96 and 0.78, respectively).

Conclusion

Both the IBUS-SAS and SUS-CD can evaluate disease activity in CD and exhibited a significant correlation with activity indices and inflammatory biomarkers.

Clinical trial registration

ChiCTR2200055221

Keywords:

• Crohn’s disease
• IBUS-SAS
• SUS-CD
• disease activity
• inflammatory biomarkers

Acknowledgments

The authors would like to acknowledge and thank the patients who participated in this study and Yali Wang (Department of Ultrasound), Qing Xu (Department of Radiology), Quanrongzi Wang (Department of Radiology) for their clinical support of this work.

Ethical statement

We conducted the study following the Declaration of Helsinki. The Institutional Review Board of the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University reviewed and approved the study protocol (2022-SR-349). The study’s waiver of consent was approved. All data were kept confidential.

Patient consent statement

Without any prospective interventions or control groups, this study was retrospective and descriptive. As a result, the study’s waiver of consent was approved. Every effort was made to keep the data confidential.

Disclosure statement

The authors have no conflicts of interest to declare.

Data availability statement

The manuscript has not been published previously, and is not under consideration (in whole or in part) for publication elsewhere.

Permission to reproduce material from other sources

NO

Additional information

Funding

The study wasn’t supported by any grants.